2021
Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19
Santin A, Scheim D, McCullough P, Yagisawa M, Borody T. Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19. New Microbes And New Infections 2021, 43: 100924. PMID: 34466270, PMCID: PMC8383101, DOI: 10.1016/j.nmni.2021.100924.Peer-Reviewed Original ResearchMultifaceted drugSARS-CoV-2 spike proteinCOVID-19SARS-CoV-2Such inpatientsOutpatient treatmentClinical trialsDevastating tropical diseasesGlobal scourgeRelative riskCOVID-19 fatalitiesIVM treatmentTreatment RCTsAnimal modelsExcess deathsFull efficacyInfectious diseasesTropical diseasesSpike proteinIvermectinTreatmentDiseaseBiological mechanismsDrugsDeath
2019
Synergistic clinical efficacy of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma
Tymon-Rosario J, Zeybek B, Han C, Santin AD. Synergistic clinical efficacy of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. Annals Of Translational Medicine 2019, 0: s308. PMID: 32016027, PMCID: PMC6976388, DOI: 10.21037/atm.2019.10.28.Peer-Reviewed Original ResearchPlatinum-based chemotherapyOvarian cancerInitial platinum-based chemotherapyPlatinum-resistant ovarian carcinomaGynecologic cancer deathStandard treatment regimenCancer respondMost patientsTreatment regimenClinical efficacyCancer deathOvarian carcinomaCommon causeDeath rateCancerPrecision medicineChemotherapyPatientsToxic effectsDeathPembrolizumabRegimenCarcinomaTherapyNiraparib